Express Scripts Says Still Reviewing Gilead Drugs
This article is for subscribers only.
Gilead Sciences Inc.’s top-selling hepatitis C drug, Harvoni, has been removed from Express Scripts Holding Co.’s list of excluded drugs for next year and will be reviewed for potential coverage, according to the pharmacy benefits manager.
Gilead is facing a number of challenges in sustaining the record-breaking sales from its hepatitis pills. With both AbbVie Inc. and Merck & Co. offering similar products, prices are being driven down. AbbVie had signed an exclusive deal with Express Scripts in December 2014, which helped it to get a foothold in the market despite having a less convenient treatment than Gilead.